3 completed, 1 terminated. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow perphenazine GABA ester: new trials by email Literature Review of perphenazine GABA ester trials Research Report on perphenazine GABA ester
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia CYP-1020, Risperidone - Schizophrenia, Cognitive Effect on Schizophrenic Patients | Phase 2 / Phase 3 | Terminated | BioLineRx, Ltd. | 269 | 2011-05-01 | 2014-09-18 |
| A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study BL - 1020, Placebo, Risperidone - Schizophrenia | Phase 2 | Completed | BioLineRx, Ltd. | 360 | 2008-07-01 | 2010-06-29 |
| Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 BL-1020, BL-1020 10-30 mg, risperidone - Schizophrenia | Phase 2 | Completed | BioLineRx, Ltd. | 220 | 2008-06-01 | 2010-06-29 |
| Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder BL-1020, BL 1020 High Dose - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | BioLineRx, Ltd. | 90 | 2007-06-01 | 2009-07-21 |
Schizophrenia (4) · Psychotic Disorders (1)
BioLineRx, Ltd. (4)
Romania (2) · United States (2) · India (1) · Israel (1) · Moldova (1)
Arnon Aharon, MD (1) · Mary Ann Knisevich, MD (1) · Michael Davidson, MD (1) · Yona Geffen, Ph.D (1)